Piramal Enterprises
As of the edition of 20 October 2026, Piramal Enterprises runs 7 drugs; it is on route A at 11 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Piramal Enterprises was merged.
The records place 2 company names in this family.
- PIRAMAL PHARMA LIMITED: acquired in 2020; successor Piramal Enterprises Limited
- Piramal Enterprises Limited: merged
Drugs by status
| Status | Count |
|---|---|
| Went quiet | 3 |
| Stopped | 4 |
| Total | 7 |
Where it needs a new molecule
Route A at 11 targets, route B at 0 targets.
All 11 rows on route A or B
In the product11 company-target rows on route A or B; 8 are not shown here, and no score is.
See all 11 targets where Piramal Enterprises needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 14 trials led
- Blood and lymph: 5 trials led
- Immune system: 4 trials led